| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the preceding three months, 8 analysts have released ratings for Biomarin Pharmaceutical (NASDAQ:BMRN), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 5 | 3 | 0 | 0 |
| Last 30D | 0 | 2 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 3 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $100.88, a high estimate of $110.00, and a low estimate of $85.00. This current average has decreased by 5.05% from the previous average price target of $106.25.
The standing of Biomarin Pharmaceutical among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| George Farmer | Scotiabank | Raises | Sector Perform | $85.00 | $83.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $110.00 | - |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $110.00 | $100.00 |
| Whitney Ijem | Canaccord Genuity | Maintains | Hold | $91.00 | - |
| Christopher Raymond | Piper Sandler | Lowers | Overweight | $107.00 | $115.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $100.00 | - |
| Luca Issi | RBC Capital | Maintains | Sector Perform | $100.00 | - |
| Joel Beatty | Baird | Lowers | Outperform | $104.00 | $127.00 |
To gain a panoramic view of Biomarin Pharmaceutical's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Biomarin Pharmaceutical analyst ratings.
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Biomarin Pharmaceutical's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 20.22%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Biomarin Pharmaceutical's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 3.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Biomarin Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.41%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Biomarin Pharmaceutical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.3%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Biomarin Pharmaceutical's debt-to-equity ratio is below the industry average. With a ratio of 0.22, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BMRN
